This performance was driven by sustained demand for therapies targeting serious conditions, particularly Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis)
[DOI] [PubMed] [Google Scholar] 75.Ilic S., Drmic D., Zarkovic K., Kolenc D., Coric M., Brcic L., Klicek R., Radic B., Sever M., Djuzel V., et al
The short answer is it depends
Each treatment is customized to address the unique needs of our clients, ensuring optimal results
As such, investments in oral GLP-1s may generate value well beyond a single indication, laying the groundwork for a new generation of orally delivered biologics
Our consensus group recommends considering telemedicine evaluation at 1 month to verify the correct management of KDT, and after the first year of KDT as an alternative option, with follow-up on a 6-month basis beyond yearly onsite follow-up